Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 12, 2024

Primary Completion Date

February 23, 2024

Study Completion Date

July 31, 2026

Conditions
Prostatic Neoplasms
Interventions
DRUG

Abemaciclib

Administered orally.

DRUG

Darolutamide

Administered orally.

DRUG

LHRH agonist/antagonist

Physician's choice. Administered in accordance with the prescribing information.

Trial Locations (13)

8907

Instituto Catalan de Oncologia - Hospital Duran i Reynals, L'Hospitalet de Llobregat

10016

Laura and Isaac Perlmutter Cancer Center, New York

11501

Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola

20246

Universitaetsklinikum Hamburg-Eppendorf, Hamburg

23538

Universitätsklinikum Schleswig-Holstein, Lübeck

28009

Hospital General Universitario Gregorio Marañon, Madrid

28034

Hospital Universitario Ramón y Cajal, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

41013

Hospital Universitario Virgen Del Rocio, Seville

72622

Studienpraxis Urologie, Nürtingen

72762

Highlands Oncology Group, Springdale

81675

Klinikum Rechts Der Isar Der Technischen Universität München, Munich

06006

Hospital Infanta Cristina, Badajoz

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT05999968 - Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment | Biotech Hunter | Biotech Hunter